Advertisement
Advertisement

CRBP

CRBP logo

Corbus Pharmaceuticals Holdings, Inc.

10.17
USD
Sponsored
+0.43
+4.41%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

9.91

-0.26
-2.56%

Corbus Pharmaceuticals Holdings, Inc. Profile

About

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Info & Links

CEO

Yuval Cohen

Headquarters

500 River Ridge Drive
Norwood, MA 02062, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.corbuspharma.com

Auditor

EisnerAmper LLP

Share holders

84

Employees

36

Corbus Pharmaceuticals Holdings, Inc. Statistics

Valuation Measures

Market Capitalization2

183.61M

Enterprise Value

160.24M

Enterprise Value/EBITDA(ttm)

-1.48

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.43

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-83.53%

Return on Invested Capital(ttm)

-91.72%

Return on Assets(ttm)

-72.41%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-107.99M

Net Income Available to Common(ttm)

-101.90M

Diluted EPS(ttm)

-6.19

Share Statistics

Beta (5Y Monthly)

2.59

52-Week Change

13.00%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

19.34M

Dividend Yield

0.00%

Float4

17.88M

% Held by Insiders

3.50%

% Held by Institutions

64.64%

Balance Sheet

Total Cash(mrq)

117.94M

Total Cash Per Share(mrq)

6.10

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.71%

Quick Ratio(mrq)

7.92%

Book Value Per Share(mrq)

5.48

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.84

Free Cash Flow(ytd)

-55.21M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement